European Journal of Cancer
Volume 42, Issue 1 , Pages 24-30 , January 2006

Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes

  • Stephan Mielke

      Affiliations

    • Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg i. Br., Germany
    • Corresponding Author InformationCorresponding author. Present address: Stem Cell Allogeneic Transplant Section, Hematology Branch, DIR/NHLBI, National Institutes of Health (NIH), Building 10, CRC Room 3-5288, 10 Center Drive MSC 1202 Bethesda, MD 20892-1202, USA. Tel.: +1 301 402 3294; fax: +1 301 496 8396.
    • ,
  • Alex Sparreboom

      Affiliations

    • Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD, USA
    • Department of Medical Oncology, Erasmus MC – Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • ,
  • Klaus Mross

      Affiliations

    • Tumor Biology Center of Freiburg at the Albert-Ludwigs University, Freiburg i. Br., Germany

Received 15 June 2005 ,Accepted 17 June 2005.

References 

  1. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93:2325–2327
  2. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med. 1995;332:1004–1014
  3. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263–1268
  4. Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590–1598
  5. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst USA. 1998;90:300–306
  6. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8:1038–1044
  7. Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10:3708–3716
  8. Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol. 1993;11:2010–2020
  9. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European–Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654–2666
  10. Berger T, Malayeri R, Doppelbauer A, et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer. 1997;33:1393–1399
  11. Chaudhry V, Rowinsky EK, Sartorius SE, et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994;35:304–311
  12. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology. 1989;39:368–373
  13. Postma TJ, Vermorken JB, Liefting AJ, et al. Paclitaxel-induced neuropathy. Ann Oncol. 1995;6:489–494
  14. van Gerven JM, Moll JW, van den Bent MJ, et al. Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer. 1994;30A:1074–1077
  15. Rowinsky EK, Chaudhry V, Cornblath DR, et al. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr. 1993;15:107–115
  16. Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol. 1998;16:153–158
  17. Akerley W, Herndon JE, Egorin MJ, et al. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003;97:2480–2486
  18. Seidman AD, Hudis CA, Albanel J, et al. Dose–dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol. 1998;16:3353–3361
  19. Mielke S, Mross K, Gerds TA, et al. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3h. Anticancer Drugs. 2003;14:785–792
  20. Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001;19:4216–4223
  21. Yasuda K, Igishi T, Kawasaki Y, et al. Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Oncology. 2003;65:224–228
  22. Mielke S, Sparreboom A, Steinberg SM, et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res. 2005;11:4843–4850
  23. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665–667
  24. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA. 1980;77:1561–1565
  25. Crossin KL, Carney DH. Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell. 1981;27:341–350
  26. Dustin P. Microtubules. Sci Am. 1980;243:66–76
  27. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990;82:1247–1259
  28. Yamada KM, Spooner BS, Wessells NK. Ultrastructure and function of growth cones and axons of cultured nerve cells. J Cell Biol. 1971;49:614–635
  29. Letourneau PC, Ressler AH. Inhibition of neurite initiation and growth by taxol. J Cell Biol. 1984;98:1355–1362
  30. Letourneau PC, Shattuck TA, Ressler AH. Branching of sensory and sympathetic neurites in vitro is inhibited by treatment with taxol. J Neurosci. 1986;6:1912–1917
  31. Komiya Y. Changes of fast axonal transport by taxol injected subepineurally into the rat sciatic nerve. Neurosci Res. 1992;14:159–165
  32. Masurovsky EB, Peterson ER, Crain SM, et al. Microtubule arrays in taxol-treated mouse dorsal root ganglion-spinal cord cultures. Brain Res. 1981;217:392–398
  33. Masurovsky EB, Peterson ER, Crain SM, et al. Morphological alterations in dorsal root ganglion neurons and supporting cells of organotypic mouse spinal cord-ganglion cultures exposed to taxol. Neuroscience. 1983;10:491–509
  34. Roytta M, Horwitz SB, Raine CS. Taxol-induced neuropathy: short-term effects of local injection. J Neurocytol. 1984;13:685–701
  35. Roytta M, Raine CS. Taxol-induced neuropathy: further ultrastructural studies of nerve fibre changes in situ. J Neurocytol. 1985;14:157–175
  36. Vuorinen VS, Roytta M. Taxol-induced neuropathy after nerve crush: long-term effects on regenerating axons. Acta Neuropathol (Berl). 1990;79:663–671
  37. Vuorinen VS, Roytta M. Taxol-induced neuropathy after nerve crush: long-term effects on Schwann and endoneurial cells. Acta Neuropathol (Berl). 1990;79:653–662
  38. Persohn E, Canta A, Schoepfer S, et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 2005 [Epub ahead of print].
  39. Sahenk Z, Barohn R, New P, et al. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol. 1994;51:726–729
  40. Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther. 1994;268:1051–1056
  41. de Groen PC, Aksamit AJ, Rakela J, et al. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med. 1987;317:861–866
  42. Lesser GJ, Grossman SA, Eller S, et al. The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother Pharmacol. 1995;37:173–178
  43. Wist EA, Sommer HH, Ostenstad B, et al. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol. 2004;43:11–14
  44. Yasuda K, Igishi T, Kawasaki Y, et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. Oncology. 2004;66:347–352
  45. Wiernik PH, Schwartz EL, Strauman JJ, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987;47:2486–2493
  46. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9:1704–1712
  47. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology. 2003;61:1297–1300
  48. Cavaletti G, Bogliun G, Marzorati L, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol. 2004;15:1439–1442
  49. Lauria G, McArthur JC, Hauer PE, et al. Neuropathological alterations in diabetic truncal neuropathy: evaluation by skin biopsy. J Neurol Neurosurg Psychiatry. 1998;65:762–766
  50. Lauria G, Pareyson D, Grisoli M, et al. Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies. Ann Neurol. 2000;47:104–109
  51. Argyriou AA, Polychronopoulos P, Koutras A, et al. Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted? Support Care Cancer 2005 [Epub ahead of print].
  52. National Cancer Institute. Common Toxicity Criteria version 2.0. 1999. Available from: http://ctep.cancer.gov/forms.
  53. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655
  54. Ajani JA, Welch SR, Raber MN, et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990;8:147–159
  55. Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology. 1999;53:1660–1664
  56. Briasoulis E, Karavasilis V, Tzamakou E, et al. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study. Anticancer Drugs. 2002;13:481–489
  57. Gelderblom H, Mross K, ten Tije AJ, et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol. 2002;20:574–581
  58. Mross K, Hollander N, Hauns B, et al. The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol. 2000;45:463–470
  59. Mross K, Haring B, Hollander N, et al. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial. Onkologie. 2002;25:503–508
  60. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res. 1995;1:599–606
  61. Sparreboom A, van TO, Nooijen WJ, et al. Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995;664:383–391
  62. Sparreboom A, van TO, Nooijen WJ, et al. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996;56:2112–2115
  63. Papadopoulos KP, Egorin MJ, Huang M, et al. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825mg/m2 continuous infusion over 24h) with hematopoietic support in women with metastatic breast cancer. Cancer Chemother Pharmacol. 2001;47:45–50
  64. Rowinsky EK, Jiroutek M, Bonomi P, et al. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res. 1999;5:767–774
  65. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995;13:180–190
  66. Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993;11:2127–2135
  67. Huizing MT, Giaccone G, van Warmerdam LJ, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol. 1997;15:317–329
  68. Wolff AC, Donehower RC, Carducci MK, et al. Phase I study of docosahexaenoic acid-paclitaxel: a taxane–fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res. 2003;9:3589–3597
  69. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389–400
  70. Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain. 2002;98:195–203
  71. Durand JP, Goldwasser F. Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. Anticancer Drugs. 2002;13:777–780
  72. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22:2909–2917
  73. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003;25:81–104
  74. Verstappen CC, Postma TJ, Geldof AA, et al. Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation. Anticancer Res. 2004;24:2337–2341
  75. Openshaw H, Beamon K, Synold TW, et al. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res. 2004;10:461–467
  76. Leong SS, Tan EH, Fong KW, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2003;21:1767–1774
  77. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology. 2005;64:26–31
  78. Hamaguchi T, Matsumura Y, Suzuki M, et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Brit J Cancer. 2005;92:1240–1246
  79. Harris JW, Rahman A, Kim BR, et al. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 1994;54:4026–4035
  80. Rahman A, Korzekwa KR, Grogan J, et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 1994;54:5543–5546
  81. Sparreboom A, van AJ, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA. 1997;94:2031–2035

PII: S0959-8049(05)00843-9

doi: 10.1016/j.ejca.2005.06.030

European Journal of Cancer
Volume 42, Issue 1 , Pages 24-30 , January 2006

Article Tools

* Image Usage & Resolution